{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:39:48Z","timestamp":1777505988028,"version":"3.51.4"},"reference-count":34,"publisher":"Portland Press Ltd.","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,8,18]]},"abstract":"<jats:p>One of the hallmarks of AD (Alzheimer's disease) is the formation of senile plaques in the brain, which contain fibrils composed of A\u03b2 (amyloid \u03b2-peptide). According to the \u2018amyloid cascade\u2019 hypothesis, the aggregation of A\u03b2 initiates a sequence of events leading to the formation of neurofibrillary tangles, neurodegeneration, and on to the main symptom of dementia. However, emphasis has now shifted away from fibrillar forms of A\u03b2 and towards smaller and more soluble \u2018oligomers\u2019 as the main culprit in AD. The present chapter commences with a brief introduction to the disease and its current treatment, and then focuses on the formation of A\u03b2 from the APP (amyloid precursor protein), the genetics of early-onset AD, which has provided strong support for the amyloid cascade hypothesis, and then on the development of new drugs aimed at reducing the load of cerebral A\u03b2, which is still the main hope for providing a more effective treatment for AD in the future.<\/jats:p>","DOI":"10.1042\/bse0560099","type":"journal-article","created":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T11:18:39Z","timestamp":1408360719000},"page":"99-110","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Amyloid \u03b2-peptide and Alzheimer's disease"],"prefix":"10.1042","volume":"56","author":[{"given":"David","family":"Allsop","sequence":"additional","affiliation":[{"name":"Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Mayes","sequence":"additional","affiliation":[{"name":"Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2014,8,18]]},"reference":[{"key":"2021111610193828700_B1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer's disease: genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol. Rev."},{"key":"2021111610193828700_B2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer's disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"2021111610193828700_B3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J. Int. Med."},{"key":"2021111610193828700_B4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3233\/JAD-122440","article-title":"A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia","volume":"36","author":"Eckerstr\u00f6m","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"2021111610193828700_B5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jalz.2013.02.003","article-title":"2013 Alzheimer's disease facts and figures","volume":"9","author":"Thies","year":"2013","journal-title":"Alzheimers Dement."},{"key":"2021111610193828700_B6","author":"Alzheimer's Disease International: World Alzheimer Report 2009"},{"key":"2021111610193828700_B7","first-page":"27","article-title":"Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology","volume":"76","author":"Anand","year":"2014"},{"key":"2021111610193828700_B8","author":"Dementia 2010: the economic burden of dementia and associated research funding in the United Kingdom"},{"key":"2021111610193828700_B9","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111610193828700_B10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/197192b0","article-title":"Paired helical filaments in electron microscopy of Alzheimer's disease","volume":"197","author":"Kidd","year":"1963","journal-title":"Nature"},{"key":"2021111610193828700_B11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00401-012-0996-2","article-title":"The genetics and neuropathology of Alzheimer's disease","volume":"124","author":"Schellenberg","year":"2012","journal-title":"Acta Neuropath."},{"key":"2021111610193828700_B12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"2021111610193828700_B13","doi-asserted-by":"crossref","first-page":"17401","DOI":"10.1074\/jbc.M300629200","article-title":"Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis","volume":"278","author":"Barnham","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2021111610193828700_B14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0896-6273(93)90315-I","article-title":"Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the \u03b2-amyloid precursor protein","volume":"10","author":"Mattson","year":"1993","journal-title":"Neuron"},{"key":"2021111610193828700_B15","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1523\/JNEUROSCI.14-04-02117.1994","article-title":"A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth","volume":"14","author":"Small","year":"1994","journal-title":"J. Neurosci."},{"key":"2021111610193828700_B16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0896-6273(01)00496-2","article-title":"Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila","volume":"32","author":"Gunawardena","year":"2001","journal-title":"Neuron"},{"key":"2021111610193828700_B17","doi-asserted-by":"crossref","first-page":"44670","DOI":"10.1074\/jbc.M204379200","article-title":"Overexpression of Alzheimer's disease amyloid-\u03b2 opposes the age-dependent elevations of brain copper and iron","volume":"277","author":"Maynard","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2021111610193828700_B18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0006-8993(99)01861-2","article-title":"Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice","volume":"842","author":"White","year":"1999","journal-title":"Brain Res."},{"key":"2021111610193828700_B19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jnr.10737","article-title":"ADAMs family members as amyloid precursor protein \u03b1-secretases","volume":"74","author":"Allinson","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"2021111610193828700_B20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","article-title":"\u03b2-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE","volume":"286","author":"Vassar","year":"1999","journal-title":"Science"},{"key":"2021111610193828700_B21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00709-013-0494-y","article-title":"The very many faces of presenilins and the \u03b3-secretase complex","volume":"250","author":"Smolarkiewicz","year":"2013","journal-title":"Protoplasma"},{"key":"2021111610193828700_B22","first-page":"605","article-title":"Clearance of Alzheimer's A\u03b2 peptide: the many roads to perdition","volume":"43","author":"Tanzi","year":"2004","journal-title":"Neuron"},{"key":"2021111610193828700_B23","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.psyneuen.2007.05.015","article-title":"Genetic heterogeneity of Alzheimer's disease: complexity and advances","volume":"32","author":"Lambert","year":"2007","journal-title":"Psychoneuroendocrinology"},{"key":"2021111610193828700_B24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","article-title":"Amyloid deposition as the central event in the aetiology of Alzheimer's disease","volume":"12","author":"Hardy","year":"1991","journal-title":"Trends Pharmacol. Sci."},{"key":"2021111610193828700_B25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(12)70307-1","article-title":"A presenilin 1 mutation in the first case of Alzheimer's disease","volume":"12","author":"M\u00fcller","year":"2013","journal-title":"Lancet Neurol."},{"key":"2021111610193828700_B26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer's disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"key":"2021111610193828700_B27","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"2021111610193828700_B28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0006-8993(01)03228-0","article-title":"Apolipoprotein E modulates Alzheimer's A\u03b2(1\u201342)-induced oxidative damage to synaptosomes in an allele-specific manner","volume":"924","author":"Lauderback","year":"2002","journal-title":"Brain Res."},{"key":"2021111610193828700_B29","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1073\/pnas.050004797","article-title":"Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease","volume":"97","author":"Holtzman","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111610193828700_B30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12035-013-8424-8","article-title":"TREM2 in Alzheimer's disease","volume":"48","author":"Jiang","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"2021111610193828700_B31","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"A\u03b2 oligomers: a decade of discovery","volume":"101","author":"Walsh","year":"2007","journal-title":"J. Neurochem."},{"key":"2021111610193828700_B32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/85059","article-title":"Mice deficient in BACE1, the Alzheimer's \u03b2-secretase, have normal phenotype and abolished \u03b2-amyloid generation","volume":"4","author":"Luo","year":"2001","journal-title":"Nature Neurosci."},{"key":"2021111610193828700_B33","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.bbamem.2013.06.005","article-title":"\u03b3-Secretase inhibitors and modulators","volume":"1828","author":"Golde","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111610193828700_B34","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1111\/j.1471-4159.2011.07458.x","article-title":"Clinical trials in Alzheimer's disease: immunotherapy approaches","volume":"120","author":"Delrieu","year":"2012","journal-title":"J. Neurochem."}],"container-title":["Essays in Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article-pdf\/doi\/10.1042\/bse0560099\/736082\/bse0560099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article-pdf\/doi\/10.1042\/bse0560099\/736082\/bse0560099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T10:30:48Z","timestamp":1637058648000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article\/doi\/10.1042\/bse0560099\/78390\/Amyloid-peptide-and-Alzheimer-s-disease"}},"subtitle":[],"editor":[{"given":"Sarah","family":"Perrett","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,8,18]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1042\/bse0560099","relation":{},"ISSN":["0071-1365","1744-1358"],"issn-type":[{"value":"0071-1365","type":"print"},{"value":"1744-1358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,18]]}}}